AARDEX Group

Breaking News

Placebo and adherence: Is a complicated relationship compromising clinical trial effectiveness?

In 1920, The Lancet published a paper authored by T.C. Graves entitled ‘Commentary on a case of hystero-epilepsy with delayed puberty: Treated with testicular extract’. While the article was not the first to mention the placebo effect, it is recognised … Read More

Digital adherence measurement in clinical trials: The era of clearer insight is already here

Among the many forces that can influence clinical trials, arguably not enough attention is paid to status quo bias.   A common phenomenon, status quo bias can explain why any proposed departure from existing expectations or dominant practice can be … Read More

Enhancing Medication Adherence in Rare Disease Clinical Trials

In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected … Read More

Approaches to Medication Adherence

Reassessing Approaches and Attitudes to Medication Adherence in Drug Trials

It is human nature for people to trust the things that are known to them ahead of the things that are not. Familiarity, after all, brings with it a sense of comfort and reassurance. It is perhaps understandable, therefore, that … Read More

Ignorance of ALCOA+ is a Risk to Regulatory Compliance

Ignorance of ALCOA+ is a Risk to Regulatory Compliance

In this article, AARDEX Group Quality Manager, Oana Paun, discusses ALCOA+ and its importance for achieving regulatory compliance. For those with a scientific ear, it can be reassuring when you hear ideas discussed in terms of data. The word alone … Read More

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological … Read More

Bias in clinical Research

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality, … Read More

Dose Optimization

Dose Optimization: Getting to the Root of a Long-Term Issue

In this article, Dr. Vrijens shares his thoughts on the need for dose optimization in the interests of balancing safety and efficacy. How we use language has a huge bearing on the meaning we convey. Take the word ‘overdose’, for … Read More

Medication Adherence Data

From Estimation to Calculation: Exploring the Power of Medication Adherence Data 

In this article, Dr. Bernard Vrijens discusses the importance of medication adherence data in clinical trials and why medication adherence should be a calculation, not an estimation. The world is today collecting a mind-blowing amount of data. Indeed, IDC calculates that about … Read More

Medication Non-Adherence

ROI: Understanding the True Cost of Medication Non-Adherence in Clinical Trials

In this article, our Scientific Lead, Bernard Vrijens, discusses the influence of medication non-adherence on ROI in clinical trials. Get ready for an insightful read! Fraught with risk yet pivotal to the future success of a drug candidate, clinical trials … Read More